Results 281 to 290 of about 2,246,656 (386)

The efficacy of Telitacicept in Childhood‐onset Systemic Lupus Erythematosus: a prospective multi‐center cohort study with IPTW‐adjusted comparison to a historical control group treated with Belimumab

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The therapeutic effects of Telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with Belimumab combined with SoC. Methods We performed a prospective cohort study across 7 tertiary hospitals in China, enrolling patients ...
Chong Luo   +15 more
wiley   +1 more source

Dying From Dengue Encephalitis in the Absence of DHF: A Case Report. [PDF]

open access: yesCase Rep Infect Dis
Kasuni Suwandika WA   +6 more
europepmc   +1 more source

A novel treatment of biogas digestate waste for biochar production and its adsorption of methylene blue and malachite green in a binary system

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract This study presents a novel treatment of biogas digestate to produce biochar at processing temperatures of 500–700 °C. The resulting biochar was applied for the simultaneous removal of methylene blue (MB) and malachite green (MG) in a binary system.
Van Hau Duong   +10 more
wiley   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy